BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HRS-4642 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HRS-4642\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07894679-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:HRS-4642: Phase 1 readout est. (NCT07894679)
DESCRIPTION:HRS-4642\, phase 1.\nStudy: Effect of Itraconazole on the Pharm
 acokinetics of Intravenous HRS-4642 in Healthy Participants\nEstimated pri
 mary completion: November 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/hrs-4642#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07894679
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06620848-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRS-4642: Phase 2 readout est. (NCT06620848)
DESCRIPTION:HRS-4642\, phase 2.\nStudy: A Study of HRS-4642 Monotherapy or 
 in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract
  Tumors.\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/hrs-4642#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06620848
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07906691-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:HRS-4642: Phase 1 readout est. (NCT07906691)
DESCRIPTION:HRS-4642\, phase 1\, Pancreatic Cancer.\nStudy: A Study to Asse
 ss the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Followin
 g Intravenous Infusion in Healthy Participants\nEstimated primary completi
 on: February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hr
 s-4642#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07906691
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06770452-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:HRS-4642: Phase 2 readout est. (NCT06770452)
DESCRIPTION:HRS-4642\, phase 2\, Pancreatic Cancer.\nStudy: HRS-4642 With N
 imotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreati
 c Cancer Patients\nEstimated primary completion: 1 February 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/hrs-4642#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06770452
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06520488-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:HRS-4642: Phase 1/2 readout est. (NCT06520488)
DESCRIPTION:HRS-4642\, phase 1/2.\nStudy: A Study of HRS-4642 in Combinatio
 n With Antineoplastic Agents in Advanced Solid Tumors\nEstimated primary c
 ompletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/hrs-4642#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06520488
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547736-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:HRS-4642: Phase 2 readout est. (NCT06547736)
DESCRIPTION:HRS-4642\, phase 2\, Pancreatic Cancer.\nStudy: Exploratory Pla
 tform Research on Precision Therapy of Advanced Pancreatic Cancer\nEstimat
 ed primary completion: March 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/hrs-4642#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06547736
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06938282-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:HRS-4642: Phase 2 readout est. (NCT06938282)
DESCRIPTION:HRS-4642\, phase 2\, Pancreatic Cancer.\nStudy: An Exploratory 
 Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemother
 apy for Pancreatic Cancer\nEstimated primary completion: 30 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/hrs-4642#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06938282
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07240766-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:HRS-4642: Phase 2 readout est. (NCT07240766)
DESCRIPTION:HRS-4642\, phase 2.\nStudy: HRS-4642 in Combination With Nimotu
 zumab and Chemotherapy for BRPC With KRAS G12D Mutation\nEstimated primary
  completion: 15 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/hrs-4642#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07240766
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427239-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:HRS-4642: Phase 1/2 readout est. (NCT06427239)
DESCRIPTION:HRS-4642\, phase 1/2\, Pancreatic Cancer.\nStudy: Exploratory C
 linical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Ad
 vanced Pancreatic Ductal Adenocarcinoma\nEstimated primary completion: Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-4642#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06427239
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06587061-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:HRS-4642: Phase 2 readout est. (NCT06587061)
DESCRIPTION:HRS-4642\, phase 2\, Pancreatic Cancer.\nStudy: HRS-4642 in Com
 bination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Canc
 er\nEstimated primary completion: June 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/hrs-4642#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06587061
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07131514-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:HRS-4642: Phase 2 readout est. (NCT07131514)
DESCRIPTION:HRS-4642\, phase 2\, Pancreatic Cancer.\nStudy: HRS-4642 in Com
 bination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for
  Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer\nEstimated primar
 y completion: June 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/hrs-4642#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07131514
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07296341-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:HRS-4642: Phase 1/2 readout est. (NCT07296341)
DESCRIPTION:HRS-4642\, phase 1/2\, Pancreatic Cancer.\nStudy: HRS-4642 Comb
 ination With Other Antitumor Therapies in Patients With Solid Tumors\nEsti
 mated primary completion: October 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/hrs-4642#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07296341
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07438106-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:HRS-4642: Phase 2 readout est. (NCT07438106)
DESCRIPTION:HRS-4642\, phase 2\, Pancreatic Cancer.\nStudy: A Phase II Stud
 y of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Convers
 ion Therapy for Locally Advanced Pancreatic Cancer\nEstimated primary comp
 letion: October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /hrs-4642#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07438106
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691593-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:HRS-4642: Phase 2 readout est. (NCT07691593)
DESCRIPTION:HRS-4642\, phase 2\, Pancreatic Cancer.\nStudy: Neoadjuvant HRS
 -4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cance
 r\nEstimated primary completion: October 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/hrs-4642#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07691593
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503639-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:HRS-4642: Phase 2 readout est. (NCT07503639)
DESCRIPTION:HRS-4642\, phase 2.\nStudy: Umbrella Trial of Neoadjuvant Thera
 py for Locally Advanced Colorectal Cancer\nEstimated primary completion: A
 pril 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-4642#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07503
 639
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806058-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:HRS-4642: Phase 1/2 readout est. (NCT07806058)
DESCRIPTION:HRS-4642\, phase 1/2\, Pancreatic Cancer.\nStudy: An Open-Label
 \, Multicenter\, Phase IB/II Clinical Study of HRS-7172 in Combination Wit
 h Antitumor Therapy in Participants With Solid Tumors\nEstimated primary c
 ompletion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/hrs-4642#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07806058
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232875-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:HRS-4642: Phase 3 readout est. (NCT07232875)
DESCRIPTION:HRS-4642\, phase 3\, Pancreatic Cancer.\nStudy: HRS 4642 Inject
 ion Combined With AG Versus Placebo Combined With AG Therapy in First-Line
  Advanced or Metastatic Pancreatic Cancer\nEstimated primary completion: A
 pril 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-4642#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07232
 875
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900789-11069@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:HRS-4642: Phase 3 readout est. (NCT07900789)
DESCRIPTION:HRS-4642\, phase 3\, Pancreatic Cancer.\nStudy: HRS-4642 Combin
 ed With Antitumor Agents for the Treatment of Perioperative Pancreatic Can
 cer\nEstimated primary completion: 30 November 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/hrs-4642#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07900789
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
